Research Index

GHRH(1-29)NH2 increased height velocity in 12 of 18 GH-deficient children, with 8 showing sustained worthwhile response over 6-18 months of twice-daily injections.

Once-weekly semaglutide 2.4mg achieved 14.9% weight loss over 68 weeks vs 2.4% placebo in adults with obesity; 69.1% achieved >=10% weight loss.

SCALE Diabetes trial: liraglutide 3.0mg achieved significant weight loss in adults with type 2 diabetes and overweight/obesity compared to placebo.

Study investigating GHRP-6's role in regulating growth hormone secretion, examining mechanisms by which this hexapeptide modulates pituitary GH release.

SURMOUNT-1: In 2,539 adults with obesity, once-weekly tirzepatide (GIP/GLP-1 dual agonist) achieved substantial sustained weight loss over 72 weeks.

Ipamorelin identified as a potent pentapeptide GH secretagogue with high GH-releasing efficacy in vitro and in vivo, demonstrating selectivity for GH secretion.

AOD9604 (GH lipolytic fragment) reduced body weight and body fat in obese mice after 14 days, increasing beta(3)-adrenergic receptor expression in fat cells.

Phase 2 trial of retatrutide (GLP-1/GIP/glucagon triple agonist) in adults with obesity demonstrated dose-dependent weight loss and acceptable safety profile.

Pralmorelin (GHRP-2) is an orally active synthetic growth hormone-releasing peptide that mimics ghrelin, regulating GH release, bone/muscle growth, and food intake.

Palatin developed PT-141 (bremelanotide) as a nasal spray for erectile dysfunction and female sexual dysfunction, completing Phase IIb trials with Phase III planned.

CJC-1295, a long-acting GHRH analog, prolonged GH and IGF-1 secretion in healthy adults across two randomized placebo-controlled dose-escalation trials (28 and 49 days).

Phase 2 trial: survodutide (GLP-1/glucagon dual agonist) demonstrated significant weight loss across dose levels in adults with obesity across 12 countries.

BPC 157 significantly accelerated tendon explant outgrowth, cell survival, and cell migration in rat Achilles tendon transection, enhancing tendon healing.

Tesamorelin is the first and only approved treatment for reducing excess abdominal fat in HIV lipodystrophy, significantly reducing visceral adipose tissue over 26 weeks.

Doping control method for detecting TB-500 (synthetic LKKTETQ from thymosin beta-4) in equine urine and plasma by LC-MS, targeting misuse in horse racing.

Case report: 39-year-old male developed systemic toxicity, sympathomimetic excess, and rhabdomyolysis after injecting 6mg of melanotan II purchased online for tanning.

Copper-free GHK increased keratinocyte proliferation and showed stem cell recovering effects in cultured human keratinocytes and skin equivalent models for skincare.

Heptapeptide Selank exhibits prolonged anti-anxiety and nootropic effects, with molecular mechanisms distinct from GABA-targeting anxiolytics, avoiding dependence issues.